CRS‐2. Angiotensin‐converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), sacubitril/valsartan (ARNI), mineralocorticoid antagonists, and SGLT2 inhibitors were all studied for their involvement in CRS‐2 therapy. The gene discussed is SLC5A2; the disease is congenital rubella syndrome.